Frontlight ResearchEarly access
CompletedPhase 2
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Key facts
- Who runs it
- Xeris Pharmaceuticals
- Where
- Chula Vista, Miami Lakes, Montclair, Renton, San Antonio, and Sugar Land, United StatesSee the 6 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 46 people enrolled
- Started
- 15 May 2023
- Ended
- 22 Feb 2024
- Type of study
- Interventional
- Treatments tested
- levothyroxine sodium
- Record updated
- 3 July 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Provide written informed consent
- Male or female between the ages of 18 and 65 years (inclusive) at Screening, with chronic hypothyroidism and on a stable dose of oral levothyroxine (Synthroid or an FDA-approved generic equivalent to Synthroid) or, if in the pharmacokinetic substudy, Synthroid only for at least 3 months
- Thyroid stimulating hormone (TSH) within the normal range at Screening (central laboratory) and at least 3 months prior to Screening (documented by local laboratory)
- Free thyroxine within the normal range at Screening (central laboratory)
Who cannot take part
- History of hypersensitivity to levothyroxine (any formulation)
- Current dose of oral levothyroxine, based on body weight >2 μg/kg/day
- Current levothyroxine total daily dose either <50 μg or >375 μg
- Current use of combined thyroid treatment (i.e., Synthroid plus liothyronine or Synthroid plus Armour Thyroid) and/or any other levothyroxine aside from those used in the study
Where in United States
- ProSciento, Inc.Chula Vista, United States
- Panax Clinical Research, LLCMiami Lakes, United States
- Catalina Research Institute, L.L.C.Montclair, United States
- Rainier Clinical Research CenterRenton, United States
- American Research CorporationSan Antonio, United States
- Mt Olympus Medical Research, LLCSugar Land, United States
About the trial
What the trial wants to find out
This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of XP-8121(levothyroxine sodium) after once weekly subcutaneous injections. This study includes the following periods: Screening, Titration Period, and Maintenance Period. The study will conclude with an End of Maintenance Visit or Early Termination (ET) Visit.
The group in the trial
- XP-8121Treatment being tested
XP-8121 100 to 1500 μg subcutaneous injection
Treatment: levothyroxine sodium
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2, Multicenter, Non-Randomized, Open-Label, Single Arm, Self-controlled Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
- Record updated
- 3 July 2025